2022
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
Dohm A, Tang J, Mills M, Liveringhouse C, Sandoval M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. Journal Of Neurosurgery 2022, 138: 1600-1607. PMID: 36681988, DOI: 10.3171/2022.9.jns221896.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesCancer brain metastasesSystemic therapyBrain metastasesStereotactic radiosurgeryCheckpoint inhibitorsLocal controlGrowth factor receptor tyrosine kinase inhibitorsSingle-fraction stereotactic radiosurgeryReceptor tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsKinase inhibitorsChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesTyrosine kinase inhibitorsBM diagnosisIntracranial controlBM patientsOverall survivalPredicting Stereotactic Radiosurgery Dose Maps from Pre-Therapy MR Images using a Deep Neural Network
Pandey S, Kutuk T, Mills M, Abdalah M, Stringfield O, Latifi K, Robinson T, Moreno W, Ahmed K, Raghunand N. Predicting Stereotactic Radiosurgery Dose Maps from Pre-Therapy MR Images using a Deep Neural Network. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2022 DOI: 10.58530/2022/4966.Peer-Reviewed Original ResearchDose mapsStereotactic radiosurgeryPre-RTMR imagingRadiation treatmentAsymptomatic brain metastasesMR images of patientsImages of patientsDoses of radiation treatmentVoxel intensitiesTumor controlBrain metastasesTumor responsePre-therapyTumorHealthy brainBrainRadiosurgeryMetastasizingMetastasisPatientsBreastDoseUpfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Yu H, Oliver D, Ahmed K. Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e14. DOI: 10.1016/j.ijrobp.2021.10.186.Peer-Reviewed Original ResearchDistant intracranial controlEGFR-positive NSCLCBrain metastasesRadiation therapyBM diagnosisOverall survivalLocal controlMultivariate analysisSingle-institution retrospective analysisGeneration tyrosine kinase inhibitorsCentral nervous system penetrationUpfront radiation therapyKaplan-Meier methodProportional hazards modelTyrosine kinase inhibitorsMATERIAL/METHODSIntracranial radiation therapyIntracranial controlUpfront treatmentDS-GPAClinical outcomesResults MedianRetrospective analysisTreatment groupsHazards model
2021
Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone
Dohm A, Tang J, Mills M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e567. DOI: 10.1016/j.ijrobp.2021.07.1531.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesTiming of SRSChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesBrain metastasesCancer brain metastasesSystemic therapyRadiation necrosisStereotactic radiosurgeryCheckpoint inhibitorsOverall survivalTreatment groupsLocal controlMultivariate analysisBM patientsAlone groupClinical outcomesConventional chemotherapyGrowth factor receptor tyrosine kinase inhibitorsNivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study.
Ahmed K, Kim Y, Arrington J, Kim S, DeJesus M, Soyano A, Armaghani A, Costa R, Khong H, Rosa M, Caudell J, Diaz R, Robinson T, Etame A, Tran N, Sahebjam S, Soliman H, Forsyth P, Yu H, Han H. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: A non-randomized, open-label phase Ib study. Journal Of Clinical Oncology 2021, 39: e14010-e14010. DOI: 10.1200/jco.2021.39.15_suppl.e14010.Peer-Reviewed Original ResearchBreast cancer brain metastasesCancer brain metastasesProgression-free survivalBrain metastasesStereotactic radiosurgeryBrain metastasis controlStudy therapyControl rateMetastasis controlCertain breast cancer patientsNeuro-Oncology Brain MetastasesSystemic progression-free survivalDose of nivolumabNeurologic adverse eventsImmune checkpoint inhibitionPhase Ib studyPhase Ib trialSolid Tumors criteriaResponse Evaluation CriteriaKey eligibility criteriaTumor control rateFeasible treatment optionBreast cancer patientsBrain metastasis managementExtracranial disease
2020
RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION
Thawani C, Mills M, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION. Neuro-Oncology 2020, 22: ii181-ii182. PMCID: PMC7651564, DOI: 10.1093/neuonc/noaa215.757.Peer-Reviewed Original ResearchBreast cancer subtypesBreast cancer brain metastasesBrain metastasis diagnosisCancer brain metastasesBrain metastasesStereotactic radiationOverall survivalClinical outcomesCancer subtypesHR-/HER2TN patientsMetastasis diagnosisHormone receptorsBreast cancer patientsBrain metastasis controlBreast brain metastasesOS ratesClinical chartsInstitutional seriesMedian ageSystemic metastasesInstitutional registryCancer patientsRadiologic examinationDisease progressionClinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and Capecitabine
Mills M, Naz A, Thawani C, Walker C, Figura N, Forsyth P, Etame A, Liu J, Vogelbaum M, Yu M, Robinson T, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and Capecitabine. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e685-e686. DOI: 10.1016/j.ijrobp.2020.07.2040.Peer-Reviewed Original ResearchClinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine
Mills M, Walker C, Thawani C, Naz A, Figura N, Yu M, Robinson T, Etame A, Liu J, Vogelbaum M, Forsyth P, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e679-e680. DOI: 10.1016/j.ijrobp.2020.07.2026.Peer-Reviewed Original ResearchClinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation
Mills M, Thawani C, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. Clinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e18-e19. DOI: 10.1016/j.ijrobp.2020.02.508.Peer-Reviewed Original Research
2019
CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES
Mohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES. Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.Peer-Reviewed Original ResearchStereotactic radiotherapyMedian timeRenal cell carcinoma brain metastasesDistant brain failureStage IV RCCMedian overall survivalOptimal treatment sequenceCox regression modelStereotactic radiation therapyWarrants further investigationDistant brainEligible lesionsNivolumab administrationBrain metastasesConsecutive patientsOverall survivalClinical outcomesBrain failureKaplan-MeierRetrospective databaseHemorrhagic lesionsNivolumabRadiation therapyPatient basisPatientsOutcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiosurgery (SRS) and Fractionated Stereotactic Radiotherapy (FSRT) for Sarcoma Brain Metastases
Sim A, Ahmed K, Keller A, Figura N, Oliver D, Sarangkasiri S, Robinson T, Johnstone P, Yu M, Naghavi A. Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiosurgery (SRS) and Fractionated Stereotactic Radiotherapy (FSRT) for Sarcoma Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e120. DOI: 10.1016/j.ijrobp.2019.06.2235.Peer-Reviewed Original ResearchCDK 4/6 Inhibitors and Stereotactic Radiation in the Management of Hormone Receptor-Positive Breast Cancer Brain Metastases
Potluri T, Figura N, Oliver D, Robinson T, Etame A, Tran N, Liu J, Soliman H, Forsyth P, Sahebjam S, Yu M, Han H, Ahmed K. CDK 4/6 Inhibitors and Stereotactic Radiation in the Management of Hormone Receptor-Positive Breast Cancer Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e86. DOI: 10.1016/j.ijrobp.2019.06.2358.Peer-Reviewed Original Research
2017
Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases
Savla B, Ahmed K, Yu M, Perez B, Dinan M, Mason N, Robinson T. Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e105. DOI: 10.1016/j.ijrobp.2017.06.842.Peer-Reviewed Original Research(P019) LINAC-Based Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Brain Metastases From Sarcoma
Keller A, Yu M, Naghavi A, Robinson T, Sarangkasiri S, Etame A, Johnstone P, Ahmed K. (P019) LINAC-Based Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Brain Metastases From Sarcoma. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e20-e21. DOI: 10.1016/j.ijrobp.2017.02.116.Peer-Reviewed Original Research